1. Scrip

European Approval For Roxadustat Is Silver Lining For FibroGen

But Will Not Head Off Restructuring

 
• By Andrew McConaghie

The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.

Amsterdam, March 2020. Entrance of the office from the European Medicines Agency (EMA) in Amsterdam
Based on guidance from the EMA (pictured), the EU approval is good news for FibroGen and its partner Astellas, but does not compensate for the drug's rejection in the US.

The approval of anemia therapy roxadustat European Union has provided some good news for FibroGen, where the drug will be the first in its class and marketed by partner Astellas under the brand name Evrenzo.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas